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Abstract
Introduction: The World Health Organization (WHO) recommends that HIV-positive adults with CD4 count 5500 cells/mm3
initiate antiretroviral therapy (ART). In many countries of sub-Saharan Africa, CD4 count is not widely available or consistently
used and instead the WHO clinical staging system is used to determine ART eligibility. However, concerns have been raised
regarding its discriminatory ability to identify patients eligible to start ART. We therefore reviewed the accuracy of WHO stage
3 or 4 assessment in identifying ART eligibility according to CD4 count thresholds for ART initiation.
Methods: We systematically searched PubMed and Global Health databases and conference abstracts using a comprehensive
strategy for studies that compared the results of WHO clinical staging with CD4 count thresholds. Studies performed in sub-
Saharan Africa and published in English between 1998 and 2013 were eligible for inclusion according to our predefined study
protocol. Two authors independently extracted data and assessed methodological quality and risk of bias using the Quality
Assessment Tool for Diagnostic Accuracy Studies (QUADAS-2) tool. Summary estimates of sensitivity and specificity were derived
for each CD4 count threshold and hierarchical summary receiver operator characteristic curves were plotted.
Results: Fifteen studies met the inclusion criteria, including 25,032 participants from 14 countries. Most studies assessed
individuals attending ART clinics prior to treatment initiation. WHO clinical stage 3 or 4 disease had a sensitivity of 60% (95% CI:
4573%, Q914.26, pB0.001) and specificity of 73% (95% CI: 6083%, Q1439.43, pB0.001) for a CD4 threshold of 5200
cells/mm3 (11 studies); sensitivity and specificity for a threshold of CD4 count 5350 cells/mm3 were 45% (95% CI: 2666%,
Q1607.31, pB0.001) and 85% (95% CI: 6993%, Q896.70, pB0.001), respectively (six studies). For the threshold of CD4
count 5500 cells/mm3 sensitivity was 14% (95% CI: 1315%) and specificity was 95% (95% CI: 9496%) (one study).
Conclusions: When used for individual treatment decisions, WHO clinical staging misses a high proportion of individuals who are
ART eligible by CD4 count, with sensitivity falling as CD4 count criteria rises. Access to accurate, accessible, robust and affordable
CD4 count testing methods will be a pressing need for as long as ART initiation decisions are based on criteria other than
seropositivity.
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Introduction
At the end of 2012, an estimated 9.7 million HIV-positive
patients had initiated antiretroviral therapy (ART) worldwide,
a 30-fold increase since 2003 [1]. Despite this rapid scale-up,
39% (under 2010 World Health Organization guidelines) and
66% (under 2013 WHO guidelines) of all ART-eligible indivi-
duals are still not taking ART in low- and middle-income
countries [1]. Mathematical modelling [2] and observational
studies [3] suggest that increasing population ART coverage
could dramatically reduce HIV transmission and mortality.
The landmark HTPN052 trial showed a 96% reduction in HIV
transmission to uninfected partners in serodiscordant couples
with immediate ART initiation [4]. On the basis of this
evidence, and data supporting clinical benefit, World Health
Organization (WHO) has recently issued new ART guidance
which recommends starting ART in HIV-positive adults with a
CD4 count 5500 cells/mm3 [1].
Measurement of CD4 count is the preferred method for
ART eligibility assessment in HIV-positive patients. However,
in sub-Saharan Africa, this is still not widely available [5]. For
example, in 2012 only 11% of ART centres in Malawi had a
functioning CD4 count machine [6]. Even where CD4 count
measurement is available, quality may not be assured and
access to this service can be unreliable, requiring multiple
Munthali C et al. Journal of the International AIDS Society 2014, 17:18932
http://www.jiasociety.org/index.php/jias/article/view/18932 | http://dx.doi.org/10.7448/IAS.17.1.18932
1
expensive visits to healthcare facilities [7]. This contributes to
the high rates of pre-ART loss to follow up seen in many ART
programmes [810]. Point of care CD4 count testing has the
potential to overcome some of these barriers [11] but has
not been widely rolled out in Africa.
Where CD4 count is not immediately available, the WHO
clinical staging system is used for initial assessment of ART
eligibility. This clinical staging system was developed in 1990
based on original clinical case definitions for AIDS [12] and was
intended as a clinical method for diagnosing HIV infection
and monitoring disease progression [13,14]. It has four clinical
stages, numbered stage 1 to stage 4. The clinical stages are
hierarchical with standardized clinical parameters; stage 1 is
primary HIV infection, while individuals in stage 4 have ad-
vanced HIV disease or AIDS. Stage-defining conditions are
used to classify patients into one of the four clinical stages [15].
Over the years, the WHO clinical staging has undergone
modifications. It was first revised in 2005 [16]. The current ver-
sion, revised in 2009, has 40 clinical conditions [17]. Under the
2013 WHO ART guidelines, adults in WHO stage 3 or 4 are
considered eligible to initiate ART [1]. As well as being used to
identify individuals in need of ART, although not yet valida-
ted, WHO staging can be used in setting with limited CD4
count availability to provide a measure of programme perfor-
mance by identifying patients who have presented late for
treatment [6].
Although the WHO clinical staging system has been widely
adopted as a tool for assessing ART eligibility, healthcare
workers find it time-consuming, complex and poorly applic-
able in resource-poor settings without access to sophisticated
diagnostics [18]. Moreover, its performance as an ART eligi-
bility assessment tool has not been evaluated. We undertook
this systematic review in order to evaluate the accuracy of
the WHO clinical staging system in identifying ARTeligibility as
defined by CD4 count thresholds.
Methods
Inclusion and exclusion criteria
The review included studies published between 1 January
1998 (when combination ART became available in resource-
limited settings) and 25May 2013.We sought studies in which
WHO clinical stage and CD4 count were contemporaneously
measured in the same HIV-positive patient during ART eligi-
bility assessment. Studies were eligible for inclusion if they
presented data on the WHO clinical staging system as the
index test and CD4 count as the reference test at CD4 count
cut-offs of either 5200, 5350 or 5500 cells/mm3, the three
main cut-offs used to define ART eligibility in international
guidelines over the past decade. Randomized controlled trials,
cohort studies, cross sectional studies and studies that ana-
lyzed routinely collected data were included. For studies
where the primary objective was not to evaluate the per-
formance of the WHO clinical staging system, but where a
subgroup of participants met inclusion criteria, only data from
this subgroup were extracted for analysis. Studies conducted
in adults (]15 years old) in sub-Saharan Africa were included;
children who were excluded as different criteria are used
for assessing treatment eligibility. Studies were limited to
sub-Saharan Africa to improve comparability. Studies that
enrolled only participants in a particular WHO clinical stage
were also excluded as they presented insufficient data for
calculating test performance.
Search strategy
We searched PubMed and Global Health [19] databases
using a comprehensive search strategy following a protocol
(CRD42013004801) registered under the University of York
database for Prospectively Registered Systematic Reviews in
Health and Social Care (PROSPERO) [20] (Supplementary file).
Search terms and full search strategies for both databases
are shown in Appendices 1 and 2. We used MeSH terms, free
text and keyword terms: HIV infection; Acquired Immuno-
deficiency Syndrome; CD4 Lymphocyte Count; WHO; WHO
clinical staging; Africa south of the Sahara; poverty; develop-
ing countries. The search was limited to articles published in
English. In addition to database searches, efforts were made
to identify any additional articles that could have been missed
by screening the bibliographies of papers initially identified
as eligible for the study. We also systematically searched
through conference abstracts from the International AIDS
Society conference (IAS) and the Conference on Retroviruses
and Opportunistic Infections (CROI) from 1998 to 2012.
The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines were followed [21]
(Supplementary file). After exclusion of duplicate studies, two
reviewers (CM and PM) independently screened the titles and
abstracts of all retrieved studies to identify studies eligible
for full text review. Discrepancies were resolved by group
discussion with a third reviewer (MT). Two reviewers (CM and
PM) then independently reviewed the full text of selected
studies. A consensus meeting was held with a third reviewer
(MT) to determine final study inclusions.
Two reviewers (CM, PM) independently extracted data from
included studies. For each study, the following study informa-
tion was extracted: study setting (hospital, outpatient clinic,
antenatal care or community); type of participants (ART-naı¨ve
or reinitiating treatment); cadre of health worker perform-
ing WHO clinical staging; whether health workers had formal
study pre-training on how to perform WHO clinical staging
assessment; availability of support and routine supervision
from HIV clinical experts during the study period; and whether
the health worker performing WHO clinical staging referred to
a reference checklist of the WHO clinical staging system while
performing staging. Corresponding authors of included studies
were contacted by email to provide data where necessary.
To assess the accuracy of the WHO clinical staging system
at the three predefined CD4 count thresholds, the same two
reviewers independently extracted data on the number of
ART eligible participants who were classified as: true positive
(those correctly identified as eligible for ART by WHO staging),
false positive (those that were classified as being eligible for
ART by WHO staging but did not require ART following CD4
count testing), true negative (those correctly identified as not
eligible for ART by WHO staging) and false negative (those
that were wrongly classified as not eligible for ART by WHO
staging). Data were then summarized in two-by-two tables.
Sensitivity, specificity, positive predictive values and negative
predictive values were calculated using CD4 count thresholds
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as the referents and 95% confidence intervals were calculated
for each statistic. The WHO clinical staging system has
undergone minor incremental changes since its inception.
However, no study specified which version of the staging
system was used, so analysis was not stratified by the WHO
staging system version.
Statistical analysis
For each CD4 count threshold, pooled sensitivity and speci-
ficity were calculated using bivariate hierarchical random
effects models [22]. Heterogeneity was assessed by the Q
statistic. Coupled forest plots showing sensitivity and speci-
ficity, and hierarchical summary receiver operational curves
(HSROC) were generated. All analyses were done using Stata
version 12.1 (Statacorp, College Station, TX).
Quality and risk of bias of selected studies
The Quality Assessment Tool for Diagnostic Accuracy Studies
(QUADAS-2) was used to assess the methodological quality of
included studies and to inform judgements about risk of bias
[23].We modified the original QUADAS-2 tool by omitting two
items as they were not relevant and applicable to the study.
The omitted items were: whether participants received the
same reference standard regardless of the index test result;
and whether the index test was part of the reference test.
Two reviewers (CM and PM) independently applied nine
QUADAS-2 signalling questions across four domains to make
an overall risk of bias judgement for each study. The domains
were: selection; index test conduct; reference test conduct;
and participant flow and timing. As per QUADAS-2 guide-
lines, a study was judged to be at an overall low risk of bias if
responses to all signalling questions across four domains gave
243 duplicates removed 
Total abstracts 3136
62 full texts reviewed
2893 abstracts 
2831 abstracts not
relevant 
15 studies included
in qualitative analysis
A total of 47 studies were excluded:
42 papers were not relevant to study,
1 outside sub–Saharan Africa,
1 unpublished MSc thesis,
2 only recruited participants in either
WHO stage 1/2 or stage 3/4,
1 recruited both adults and children 
11 studies included in
quantitative analysis
4 only reported summaries of
sensitivity and specificity but
no raw data and no response
from corresponding authors
PubMed & Global
Health 3125 abstracts 
IAS
7 abstracts
CROI
3 abstracts 
Others
1 abstract
Figure 1. PRISMA flowchart summarizing articles identified through search strategy and conference abstracts.
IAS, International AIDS Society conference; CROI, the Conference on Retroviruses and Opportunistic Infections.
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no concerns about bias. If a study had one or more signalling
questions where the response indicated likely bias, it was judged
to be at high risk of bias. A judgement of ‘‘unclear’’ was given
where inadequate information to assess riskof biaswas available.
Results
Study characteristics
The search identified 2893 unique abstracts, of which 15
studies including 25,032 participants met the study inclusion
Table 1. Characteristics of included studies
Study Country Study design Description of study design Study period Population
Number of
participants
assessed
Baveewo et al.
[25]
Uganda Cross sectional Newly diagnosed HIV-positive
patients referred to ART clinic.
January 2007 to
April 2007
ARTa clinic
attendees
395
Boniphace et al.
[26]
Tanzania Cross sectional Newly diagnosed HIV-positive
patients referred to ART clinic.
April 2008 to
December 2008
ART clinic attendees 421
Carter et al. [27] Cameroon, Cote
d’Ivoire, Kenya,
Mozambique,
Rwanda, South
Africa, Uganda,
Zambia, Thailand.
Prospective
cohort
Participants were antenatal
and postnatal women screened
for ART eligibility as part of
PMTCT programme
January 2003 to
March 2008
Antenatal and
postnatal women in
PMTCTb
programme
6036
French et al.
[34]
Uganda Prospective
cohort
Newly diagnosed HIV-positive
patients referred to ART clinic.
October 1994 to
January 1995
ART clinic attendees 201
Fox et al. [28] South Africa Prospective
cohort
Small study in a large clinical
trial evaluating nurse vs. doctor
ART model of care delivery.
January 2009 ART clinic attendees 812
Ilovi et al. [33] Kenya Cross sectional Recruited newly diagnosed HIV
patients in the outpatient
clinics and hospital inpatients.
April 2010 to
February 2011
Medical inpatients
and HIV clinic
attendees
152
Jaffar et al. [35] Uganda Cross sectional Newly diagnosed HIV-positive
patients referred to ART clinic.
August 2004 to
December 2006
ART clinic attendees 4321
Kagaayi et al.
[36]
Uganda Prospective
cohort
Recruited participants from an
on-going cohort study
NRc ART clinic attendees 1221
Kassa et al. [24] Ethiopia Cross sectional Participants were enrolled from
community and hospital
inpatients medical wards.
November 1996
to April 1997;
February 1997
to April 1998
ART clinic attendees 167
Martinson et al.
[37]
South Africa Cross sectional Newly diagnosed HIV-positive
patients referred or walked-in
to ART clinic.
NR ART clinic attendees 2072
McGrath et al.
[29]
Malawi Cross sectional Newly diagnosed HIV patients
in the community
From June 2005 People in the
community
150
Miiro et al. [30] Uganda Prospective
cohort
Recruited participants from an
on-going cohort study
October 1995 to
April 2006
ART clinic attendees 2892
Morpeth et al.
[31]
Tanzania Cross sectional Newly diagnosed HIV-positive
patients referred to ART clinic.
August 2004 to
June 2005
ART clinic attendees 202
Tassie et al. [32] Malawi Cross sectional Newly diagnosed HIV-positive
patients referred to ART clinic.
NR ART clinic attendees 206
Torpey et al.
[38]
Ghana Retrospective
review of
routine
collected data
Participants were HIV patients
receiving ART in 6 public ART
clinics.
2002005 ART clinic attendees 5784
aART: antiretroviral therapy.
bPMTCT: prevention of mother to child transmission of HIV.
cNR: not reported.
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Table 2. Methodological quality and risk of bias assessment of included studies
Domains Participant selection
Conduct of index test (WHO clinical
staging system)
Conduct of reference test (CD4
count measurement) Participant flow and timing
Signalling
questions
Did study
enrol sample
of participants
representative
of the wider
population?
Were there
clear participant
selection
criteria, avoiding
inappropriate
exclusions?
Did the study
clearly
describe how
WHO staging
was
performed?
Were index test
results interpreted
without knowledge
of results of the
reference
standard?
Did the study
describe how
CD4 count
testing was
done?
Is the reference
test likely to
correctly
classify ART
eligibility?
Was the time period
between staging and
CD4 count testing
short enough not to
affect participant
stage?
Did all
participants
receive the
same
reference
standard?
Were all
participants
included in
the
analysis?
Overall
risk of bias
judgement
Baveewo et al.
[25]
Yes Yes Yes Yes Yes Yes Yes Yes Yes Low
Boniphace et al.
[26]
Yes Yes Unclear Unclear Yes Yes Unclear Yes Yes Unclear
Carter et al. [27] Yes Unclear Unclear Unclear Unclear Yes No Unclear Yes High
French et al. [34] Yes Yes Unclear Yes Yes Yes Unclear Yes Yes Unclear
Fox et al. [28] Yes Yes Unclear Unclear Unclear Yes Unclear Yes Yes Unclear
Ilovi et al. [33] Yes Unclear Yes Yes Yes Yes Yes Yes Yes Unclear
Jaffar et al. [35] Yes Yes Unclear Unclear Yes Yes Unclear Yes Yes Unclear
Kagaayi et al. [36] Yes Unclear Unclear Unclear Yes Yes Yes Yes Yes Unclear
Kassa et al. [24] Yes Yes Yes Unclear Yes Yes Unclear Yes Yes Unclear
Martinson et al.
[37]
Yes Unclear Unclear Unclear Unclear Yes No Yes Unclear High
McGrath et al.
[29]
Yes Yes Yes Yes Unclear Yes Yes Unclear Yes Unclear
Miiro et al. [30] No Yes Yes Unclear Yes Yes Unclear Yes Yes High
Morpeth et al.
[31]
Yes Unclear Yes Unclear Yes Yes Unclear Yes Yes Unclear
Tassie et al. [32] Yes Unclear Unclear Unclear Yes Yes Unclear Yes Yes Unclear
Torpey et al. [38] Yes Yes Unclear Yes Yes Yes Yes Yes Yes Unclear
Summary of methodological assessment and risk of bias judgement in included studies and their potential for risk of bias using the QUADAS 2 tool. Each item in the column represents a QUADAS 2
signalling question; each row represents the study and the response as assessed by the authors. A response of: ‘‘Yes’’ means that there was enough data reported in the study paper to provide judgement
for low risk of bias. ‘‘No’’ means that the data reported in the study paper had a potential of high risk of bias. ‘‘Unclear’’ means that there was insufficient data reported in the study paper to unable assess
the risk of bias. In the overall risk of bias judgement, a study was judged to be at low risk of bias if all signalling questions were answered ‘‘Yes.’’ If a study had one or more signalling questions with a ‘‘No’’
response, it was judged to be at high risk of bias. A judgement of ‘‘Unclear’’ was given where inadequate information to assess risk of bias was available.
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criteria (Figure 1). The characteristic of included studies are
summarized in Table 1. Eleven of the 15 studies were from
East Africa, two studies were from Southern Africa, one study
was from West Africa, and one study was a multicentre
study conducted in eight African countries. Studies’ year of
publication ranged from 1999 to 2011.
More women than men were enrolled in all of the studies
except one [24]; the proportion of women ranged from 53
to 100% of the study population. Eight studies [2532] only
enrolled participants who were ART-naı¨ve; the other studies
did not state whether participants were ART-naı¨ve or re-
initiating ART.
Study setting
Twelve of the 15 studies enrolled participants who were
newly diagnosed HIV-positive patients being assessed in
ART clinics after HIV testing and counselling (HTC) (Table 1).
The three other studies enrolled participants from a rural
community as part of a demographic and health survey (DHS)
[29], an antenatal clinic as part of a PMTCT programme [27]
and patients admitted in medical wards and assessed in an
outpatient medical assessment unit [33].
Quality and risk of bias assessment
There was considerable variation in the methodological
quality of included studies (Table 2). Only one study was
judged to be at overall low risk of bias [25] and most studies
(n11) had an unclear overall risk of bias as there was
insufficient description of one or more items. Of particular
concern was the high numbers of studies that did not provide
sufficient description of conduct of WHO clinical staging as-
sessments including whether training was provided, whether
Table 3. Conduct of WHO clinical staging and CD4 count testing in selected studies
Study
Who performed
the WHO clinical
staging?
Was WHO
Clinical staging
assessor pre-
trained?
Did assessors use a
reference checklist
when staging
patients?
Did assessors have
expert supervision
routinely provided?
Were blood samples
for CD4 count testing
taken after WHO
staging? (yes/no)
Were assessors
blinded of CD4
count results? (yes/
no/unclear)
Baveewo
et al. [25]
Cliniciansa Yes Yes NR Yes Yes
Boniphace
et al. [26]
NR NR NR NR NR Unclear
Carter et al.
[27]
Clinicians Yes NR NR NR Unclear
French et al.
[34]
NR NR Yes NR NR Yes
Fox et al.
[28]
NR NR NR NR NR Unclear
Ilovi et al.
[33]
NR NR Yes NR Yes Yes
Jaffar et al.
[35]
Clinician
(Doctors)
NR NR NR NR Unclear
Kagaayi
et al. [36]
Clinicians Yes NR Yes NR Unclear
Kassa et al.
[24]
Clinician
(Doctors)
NR Yes NR NR Unclear
Martinson
et al. [37]
Nurses and
doctors
NR NR NR NR Unclear
McGrath
et al. [29]
Medical
assistantsb
NR Yes NR Yes Yes
Miiro et al.
[30]
Clinician
(Doctors)
Yes Yes NR NR Unclear
Morpeth
et al. [31]
Healthcare
workersc
Yes Yes NR NR Unclear
Tassie et al.
[32]
NR NR NR NR NR Unclear
Torpey et al.
[38]
Clinicians Yes NR NR Yes Yes
aCadre stated as ‘‘clinician,’’ but no further definition given; bmedical assistants  health workers with a medical certificate qualification; ccadre
stated as ‘‘health worker,’’ but no further definition given. NR, not reported.
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checklists were used and whether individuals who performed
staging were blinded to CD4 count results (Table 3).
Three studies [27,30,37] were judged to be at an overall
high risk of bias. In two of these studies [27,37], participant
flow and timing could have resulted in misclassification bias:
the time period between WHO clinical staging and CD4 count
measurement was long enough to have potentially affected
the participants’ clinical stages, with CD4 counts being mea-
sured up to 91 days after staging. In the remaining study [30],
patients who were in WHO clinical stage 4 and 60 years old
were excluded. These patient selection procedures resulted in
a judgement of high risk of bias as these exclusion criteria
could have compromised index test validity and may mean
results are not applicable to the wider population of indi-
viduals undergoing WHO clinical staging in routine care.
Blinding to CD4 count results
Five studies reported that the staging assessors were blinded
to the CD4 count results [25,29,33,34,38] (Table 3). In four
of these studies blood for CD4 count measurement was
taken after WHO clinical staging [25,29,33,38]. The remaining
10/15 studies did not report when blood for CD4 count was
taken, or whether the individuals performing the clinical
staging were blinded to the CD4 count results.
Table 4. Estimates of accuracy of the WHO clinical stage 3 or 4 assessment in identifying CD4 count criteria for ART eligibility
Study
Number
true
positive
Number
false
positive
Number
true
negative
Number
false
negative
Sensitivity
(95% CI)
Specificity (95%
CI)
Positive predictive
value (95% CI)
Negative
predictive value
(95% CI)
Reference standard: CD4 count 5200 cells/mm3
Boniphace et al.
[26]
137 60 80 54 72% (6678) 57% (4966) 70% (6375) 60% (5168)
Carter et al. [27] 343 337 4408 948 27% (2429) 93% (9294) 50% (4654) 82% (8183)
Ilovi et al. [33] 76 31 36 9 89% (8195) 54% (4166) 71% (6178) 80% (6689)
French et al. [34] 55 40 83 23 71% (5980) 67% (5876) 58% (4867) 78% (6985)
Fox et al. [28] 291 110 176 225 56% (5261) 62% (5667) 73% (6877) 43% (3949)
Jaffar et al. [35] 1163 648 1400 1091 52% (5054) 68% (6670) 64% (6266) 56% (5458)
Kagaayi et al. [36] 186 106 751 178 51% (4656) 88% (8690) 64% (5869) 80% (7883)
Martinson et al.
[37]a
    61% 70% 62% 69%
McGrath et al.
[29]
5 6 89 20 20% (741) 94% (8798) 45% (2172) 82% (7388)
Miiro et al. [30]a     70% 57% 55% 72%
Morpeth et al.
[31]
82 60 33 27 75% (6683) 36% (2646) 58% (4965) 55% (4267)
Tassie et al. [32] 88 48 52 18 83% (7490) 52% (4262) 65% (5672) 74% (6283)
Torpey et al. [38] 2548 882 1284 1070 70% (6972) 59% (5661) 74% (7376) 54% (5357)
Weighted
summary
60% (4573) 73% (6083)
Reference standard: CD4 count 5350 cells/mm3
Baveewo et al.
[25]
138 15 99 143 49% (4355) 87% (7992) 90% (8494) 40% (8494)
Carter et al. [27] 506 174 3121 2235 18% (1720) 95% (9496) 74% (7178) 58% (5760)
Ilovi et al. [33] 95 14 24 21 82% (7388) 63% (4678) 87% (7992) 53% (3967)
Jaffar et al. [35] 1515 296 851 1640 48% (4650) 74% (7277) 84% (8285) 34% (3236)
McGrath et al.
[29]
11 0 69 40 22% (1135) 100% (95100) 100% (74100) 63% (5472)
Torpey et al. [38] 3147 283 691 1663 65% (6467) 71% (6874) 92% (9093) 29% (2831)
Weighted
summary
45% (2666) 85% (6993)
Reference standard: CD4 count 5500cells/mm3
Carter et al. [27] 580 100 1853 3503 14% (1315) 95% (9496) 85% (8288) 34% (3336)
Table 4 summarizes sensitivity and specificity of each included study at CD4 count cut-off values of either 5200, 5350 or 5500 cells/mm3 and
the weighted summary estimates of studies at each corresponding CD4 count cut-off. aMartinson et al. [37] & Miiro et al. [30]  the studies only
presented summary estimates; no raw data to calculate confidence intervals.
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Conduct of WHO clinical staging assessments
WHO clinical staging assessors
In eight studies, clinicians performed WHO clinical stag-
ing assessment [24,25,27,30,3538] (Table 3). Three studies
[24,30,35] specified that the clinicians were medical doctors,
while one study [37] used both nurses and doctors. In six
of these eight studies, the clinicians received formal study
pre-training in the WHO clinical staging system (Table 3). Two
studies reported that other cadres of healthcare workers
performed staging [29,31]: medical assistants in one study [29]
and unspecified pre-trained health-care workers in the other
[31]. No studies reported the length of training provided.
Reference checklist and expert support and supervision
In six studies, staging assessors used reference checklists when
assessing patients [24,25,29,30,33,34] (Table 3). Only one
study [36] reported that WHO clinical staging assessors had
regular support and routine supervision from an expert HIV
physician during the study period.
CD4 count methods
Most studies used flow cytometry methods to measure CD4
count for study participants [2426,28,30,3238]. One study
[31] used the Coulter manual method and in three studies
[27,29,37], the method was not reported. Only two studies
[25,30] reported that external laboratory quality assurance
procedures for CD4 counts were followed. The median CD4
count of participants ranged from 158 to 336 cells/mm3.
Accuracy of the WHO clinical staging
CD4 count 5200 cells/mm3
In total, 13/15 studies provided data to allow assessment of
the diagnostic test performance of WHO clinical staging 3
and 4 at CD4 count threshold of 5200 cells/mm3 (Table 4).
At this threshold, sensitivities ranged from 20 to 89%, while
specificities ranged from 36 to 93%. Positive predictive values
(PPV) ranged from 50 to 74% and negative predictive values
(NPV) ranged from 43 to 82% (Table 4). There was strong
statistical evidence of heterogeneity between studies for both
sensitivity and specificity (sensitivity: Q914.26, pB0.001;
specificity: Q1439.43, pB0.001) (Figure 2).
Eleven out of 13 studies evaluating the accuracy of WHO
clinical staging system at CD4 count 5200 cells/mm3 had
data available to allow inclusion in the random effect meta-
analysis. The pooled sensitivity at CD4 5200 cells/mm3 was
60% (95% CI: 4573%) and the pooled specificity was 73%
(95% CI: 6083%), see Figure 3.
Two studies [27,29] enrolled participants identified
through antenatal services (where provider initiated HTC
was offered) and a DHS site respectively. In these two studies
the sensitivity of WHO clinical staging was low ranging from
20 to 27% at CD4 count cut-off value of 200 cells/mm3. In
contrast, the sensitivity of the staging was relatively high
ranging from 80 to 83% in the two studies that enrolled
hospital inpatients [33,38].
CD4 count 5350 cells/mm3
Six studies used CD4 count 5350 cells/mm3 as a threshold
for ART eligibility [25,27,29,33,35,38] (Table 4). The sensitivity
Figure 2. Coupled forest plot of sensitivity and specificity of WHO clinical stage 3 or 4 assessment at CD4 count cut-off value of
5200 cells/mm3.
Sensitivity: Q914.26, pB0.001; specificity: Q1439.43, pB0.001.
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of the WHO clinical staging ranged from 18 to 82%, and
specificity ranged from 63 to 100%. The PPV ranged from
74 to 100% while the NPV ranged from 29 to 63%. There
was heterogeneity across studies for both sensitivity and
specificity, as shown in Figure 4 (sensitivity Q1607.31,
pB0.001; specificity Q896.70, pB0.001). Meta-analysis
of these six studies [25,27,29,33,35,38], showed a pooled
sensitivity of 45% (95% CI: 2666%, pB0.001) and specificity
of 85% (95% CI: 6993%, pB0.001) (Figure 5).
CD4 count 5500 cells/mm3
One study [27] evaluated the diagnostic accuracy of WHO
clinical stage 3 and 4 at a CD4 count threshold of 5500 cells/
mm3, showing a sensitivity of 14% (95% CI: 1315%) and
specificity of 95% (95% CI: 9496%), see Table 4.
Discussion
The main finding of this systematic review and meta-analysis
assessing accuracy of WHO stage 3 or 4 assessment com-
pared to CD4 count strata was the low sensitivity of the
WHO clinical staging system, with poor ability to distin-
guish between ART eligible and ineligible individuals. The
weighted summary estimates show that sensitivity wor-
sened as CD4 count threshold increased. This may lead to
patients not starting treatment despite being eligible for
ART. If CD4 counts are not available, the clinical and public
health benefits of moving to a higher threshold will be lost
[4,39,40].
In settings where laboratory-based CD4 measurements are
unavailable, alternatives are therefore required that provide
a more accurate ART eligibility assessment [4143]. The roll
out of point-of-care (POC) CD4 tests has gone some way to
meet this need; more than 2500 machines were in use in 41
low- and middle-income countries at the end of 2012 [1].
Notwithstanding this rapid scale-up, currently available POC
CD4 count machines are costly and difficult to maintain in
many low-income settings [5]. Using low-cost CD4 count
testing to guide ART eligibility has been proven to be very
cost-effective compared to WHO clinical staging at both CD4
count threshold of 5200 and 5350 cells/mm3. Low cost
CD4 testing compared to WHO clinical staging improves both
the quantity and quality of life and has an incremental cost-
effectiveness ratio (ICER) of $80 per life year gained and $85
per QALY gained [44].
Task shifting of ART care to non-physician clinicians has
been a critical strategy to support scale-up in settings where
human resources are scarce, and is recommended by the
latest WHO guidelines [1]. In two studies [30,35] included in
this review, physicians performed clinical staging assessments
while medical assistants performed clinical staging in one
study [29]. However, it is difficult to assess the effect of task
shifting on the performance of WHO clinical staging as
studies were done in different settings. A study done in
Mozambique to assess the performance of non-physician
clinician Tecnicos de Medicina in their ability to perform
clinical staging in the outpatient clinics found that the non-
physician clinicians were only able to assign a correct WHO
clinic stage in 37.5% of the patients [45]. These findings
highlight the complexities of the WHO clinical staging system,
which has case-definitions that require in-depth medical
knowledge, experience and ability to interpret laboratory
diagnostic results. As such, while the need for rapid clinical
staging continues, alternatives simplified approaches need to
be developed.
Despite its poor performance described here, retaining
WHO clinical staging as an ART eligibility assessment tool has
a number of benefits if properly performed, including in
settings where CD4 cell count is available. WHO clinical
staging provides health workers an opportunity to perform a
thorough assessment and physical examination and to screen
patients for tuberculosis and other conditions, including
those that may lead to an immune reconstitution syndrome
(IRIS) during ART initiation [46]. Removal of WHO clinical
staging completely may risk missed opportunities for identi-
fication and treatment (or provision of chemoprophylaxis) for
opportunistic infections. In addition, in settings with limited
availability of CD4 counts, like in Malawi where only 11% of
ART centres have a functional CD4 count machine, WHO
staging provides a measure of programme performance since
it identifies patients who have presented late to the clinical
services [6].
There were a number of strengths and limitations to this
study. Strengths include a broad search strategy and the use
Figure 3. Hierarchical summary receiver operating characteristic
(HSROC) of sensitivity verse specificity for the performance of
WHO stage 3 or 4 for diagnosing patients with CD4 count 5200
cells/mm3.
Each symbol represents a study, with the size of each circle being
proportional to the inverse standard error of the sensitivity and
specificity respectively. The curves represent the summary receiver
operator characteristic curves for WHO clinical stage 3 or 4. The
square represents the summary estimate of test performance while
the zone outline surrounding it represents the 95% confidence
region of the summary estimate.
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of rigorous systematic review methodology guided by a
registered protocol. A limitation of this review is the risk of
publication bias resulting from the exclusion of non-English
language studies, restricted geographical range and the
limited number of databases searched.
There are also limitations relating to the quality of
available evidence. Notably, only one of the 15 included
studies was judged to be at overall low risk of bias [25], with
a further three at high risk of bias [27,30,37]. Potential
misclassification bias was noted in two studies, with delays
between performing the index and reference test, and one
study restricted participant eligibility for inclusion so that
patients with AIDS-defining conditions were excluded, limit-
ing applicability. Moreover, the majority of studies did not
fully describe conduct of WHO clinical staging procedures,
raising concerns that there may have been potential for
information and systemic biases that could mean the
accuracy of the WHO clinical staging system was over-, or
under-estimated. Conduct of the reference test (CD4 count)
may have been suboptimal as only two studies [25,30]
reported following external quality assurance procedures.
Study estimates for sensitivity and specificity were highly
heterogeneous. However, with the small numbers of studies
we were unable to perform sensitivity analysis to examine
the effect of: year of study; individual that performed WHO
clinical staging; site of evaluation; risk of bias; or blinding to
CD4 count result on the accuracy of WHO clinical staging.
Although random-effects models were used to account for
heterogeneity, pooled estimates should be interpreted with
caution. Attempts were made to assess the performance of
WHO staging system between studies that enrolled ART-naı¨ve
participants and those that enrolled participants reinitiating
treatment. However, no studies provided such data.
Only 15 studies were identified over a period of 15 years.
This is surprising considering how widely the WHO clinical
staging system is used in sub-Saharan Africa. Although a
systematic literature search was undertaken, identifying all
studies that may have reported on accuracy of the WHO
clinical staging system was challenging as it was often not the
main focus of the study. As such, it is possible that eligible
studies have been inadvertently excluded.
Since the first WHO guidelines for ART initiation in
resource-limited settings were published in 2002, the lack
of diagnostic capacity has been recognized and all subse-
quent guidelines have stated that lack of laboratory testing
should not act as a barrier to ART initiation. This principle
remains a critical cornerstone of the public health approach.
However, continued efforts are needed to improve access
to key diagnostic tests such as CD4 cell count and viral
load measurement to accurately ascertain the need for ART,
particularly as WHO recommendations for ART change to
include patients in earlier stages of HIV infection.
This study has shown that the performance of the WHO
clinical staging system is insufficiently accurate compared to
the current gold standard ART eligibility assessment of CD4
count, with the consequence that considerable numbers of
patients will be unnecessarily delayed or missed in initiating
ART if clinical stage alone is used. The performance of WHO
Figure 4. Coupled forest plot of sensitivity and specificity of WHO clinical stage 3 or 4 assessment at CD4 count cut-off value
of B350 cells/mm3.
Sensitivity Q1607.31, pB0.001; specificity Q896.70, pB0.001.
Munthali C et al. Journal of the International AIDS Society 2014, 17:18932
http://www.jiasociety.org/index.php/jias/article/view/18932 | http://dx.doi.org/10.7448/IAS.17.1.18932
10
clinical staging varies across different study population with
hospital-based studies showing a relatively higher sensitivity
than community-based studies.
These findings strongly support calls for access to cheap,
quality assured CD4 count testing methods for as long as ART
initiation decisions are based on criteria other than seropo-
sitivity. An alternative approach to overcoming this problem
that is increasingly being considered is to remove the need
for clinical or immunological eligibility and initiate ART in all
people living with HIV irrespective of disease status.
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